Formulation and method for the treatment of fungal nail infections

Abstract

The present invention relates to a formulation and method for the treatment of fungal nail infections, such as those caused by Trichophyton rubrum and / or Aspergillus niger. The formulation of the invention comprises glucose oxidase, D-glucose and hydrogen peroxide in an aqueous solution. Advantageously, the formulation of the invention provides a two-stage hydrogen peroxide release for the treatment of the fungal nail infections.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a formulation and method for the treatment of fungal nail infections. Ideally, the fungal nail infections are caused by Trichophyton rubrum and / or Aspergillus niger. BACKGROUND TO THE INVENTION[0002]Well-known antimicrobial compositions include conventional treatments such as antiseptics and antibiotics. Other treatments include silver-containing gels, compounds containing heavy metals and solutions of hydrogen peroxide and natural and synthetic pharmaceutically active substances. However, treatments such as antibiotics have disadvantages because of the emergence of antibiotic resistance. Furthermore, high levels of hydrogen peroxide have a toxic and irritant effect. In addition, hydrogen peroxide in solution is typically unstable and it is difficult to provide a sustained delivery system for this material. Additionally, there are a number of naturally occurring antimicrobial systems known which rely on the ability of cert...

AI Technical Summary

Benefits of technology

[0052]Additionally and advantageously, the formulation of the invention is hydroscopic. The hydroscopic nature of the formulation ensures that the nail plate is hydrated at all times. This ensures that the keratin bundles present in the nail plate swell and this allows for easier penetration of the formulation and hydrogen peroxide into and through the nail plate. Due to the hydroscopic nature of the formulation, the application of an additional external source of water may not be necessary for the second tier of hydrogen peroxide release. This is a significant advantage of the present invention.

[0053]Many other treatments require penetration enhancers, however, for the above reasons the formulation of the invention does not require the use of a penetration enhancer.

[0054]Thus, the sustained release combined with the hydroscopic nature of the formulation, ensures that the formulation provides a very efficient transport mechanism for hydrogen peroxide from the formulation to the site of infection in the nail bed and / or in the nail plate.

[0056]For example, catalase is secreted by fungi as a defence mechanism. Thus, when hydrogen peroxide is applied to a fungal nail infection, catalase is secreted which results in the breakdown of hydrogen peroxide, reducing the efficacy. We have found that by ensuring the pH of the formulation is low, ideally from 4 to 8, ideally 4 to 6, this provides a less than optimum environment for catalase activity and overcomes one of the infecting fungi defence mechanisms. Thus, the low pH of the formulation prevents the degradation of hydrogen peroxide applied to the site of fungal nail infection.

[0057]Accordingly, we have found that the formulation of the invention is a very effective fungal nail infection treatment. Ideally, the fungal nail infections is caused by T. rubrum and / or A. niger.

[0058]According to a preferred embodiment of this aspect of the invention, the storage-stable endogenously produced hydrogen peroxide is bioavailable within the system at a level of at least 10, preferably 75 mg hydrogen peroxide per litre or parts per million for immediate release. However, it will be understood that the level of endogenously produced hydrogen peroxide which is immediately bioavailable within the system will depend on the amount of oxidoreductase enzyme present in the formulation. Hence, the level could be much greater than 10 or 75 mg of hydrogen peroxide per litre of the formulation if the level of oxidoreductase enzyme used is high. Thus, if the concentration of oxidoreductase enzyme and / or substrate for the oxidoreductase enzyme is increased, then the pool of endogenous hydrogen peroxide increases. For example, we have found that approximately 175 U of oxidoreductase enzyme per 100 g formulation generates an endogenous pool of approximately 10 mg hydrogen peroxide per litre. Furthermore, approximately 1400 U of oxidoreductase enzyme per 100 g formulation generates an endogenous pool of approximately 25 mg hydrogen peroxide per litre

Problems solved by technology

However, treatments such as antibiotics have disadvantages because of the emergence of antibiotic resistance.

Furthermore, high levels of hydrogen peroxide have a toxic and irritant effect.

In addition, hydrogen peroxide in solution is typically unstable and it is difficult to provide a sustained delivery system for this material.

Infection is initially a disease of the hyponychium, resulting in hyperkeratosis of the distal nail bed.

Ultimately the underside of the nail is involved which results in thickening of the nail.

The nail may become friable and crumbles away.

Sometimes the fungus proliferates in the space between the nail plate and nail bed (known as a dermatophytoma) and is often the cause of treatment failure.

The infection may worsen, spread to other uninfected locations (other nails or to the surrounding skin) or infect other people.

Infections of the fingernails may be cosmetically unacceptable.

Infections of the toenail can greatly affect the quality of life of patients and cause pain and morbidity.

Griseofulvin has been available since the 1950's and due to its fungistatic activity against dermatophytes requires long treatment periods, approximately 9 to 12 months for toenail infections, with low cure rates and high relapse rates.

However, due to hepatotoxicity its use is now restricted to fingernail infections that have failed to respond to other therapies.

Drug delivery to the nail (ungual delivery) is complicated by the physical structure of the nail.

These differences between the nail and Stratum corneum, both physical and chemical, are probably the reasons for the lack of efficacy of topical nail antifungal formulations presently on the market.

To date, conventional topical treatments for fungal nail infections all have significant limitations and have largely been unsuccessful.

In addition, designing alternative treatments has been problematic due to the chemical composition of the nail.

Images